Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept switch therapy in nAMD with type I CNV and poor response to ranibizumab or conbercept
ChiCTR2200057703Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by West China Hospital of Sichuan University. Primary endpoints: Best corrected visual acuity, Intraocular pressure and 5 more. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2200057703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057703.